Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURGICEL Powder in TKA
NCT06608992Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Polymer-based Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 4, randomised trial of oxidized and regenerated cellulose in knee osteoarthritis (OA) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Total Perioperative Blood Loss. Started Sep 2024; status: recruiting.
02
Drugs
oxidized and regenerated cellulose
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06608992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608992.